Literature DB >> 22103347

Weekly liposomal amphotericin B as secondary prophylaxis for invasive fungal infections in patients with hematological malignancies.

Lizbeth Cahuayme-Zuniga1, Russell E Lewis, Victor E Mulanovich, Dimitrios P Kontoyiannis.   

Abstract

There have been no published studies evaluating the efficacy and safety of weekly liposomal amphotericin B as secondary prophylaxis in leukemic patients with invasive fungal infections (IFIs). We found in a retrospective review of our experience with 14 such patients admitted from 2003-2009 that the use of this approach was associated with frequent relapse of IFIs (36%) and kidney injury (36%).

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22103347      PMCID： PMC3883110          DOI： 10.3109/13693786.2011.631152

Source DB:  PubMed          Journal:  Med Mycol        ISSN： 1369-3786            Impact factor:   4.076


  28 in total

1.  Case reports. Secondary prophylaxis with liposomal amphotericin B after invasive aspergillosis following treatment for haematological malignancy.

Authors:  L Mele; L Pagano; F Equitani; G Leone
Journal:  Mycoses       Date:  2001       Impact factor: 4.377

Review 2.  Risk factors for the development of invasive fungal infections in allogeneic blood and marrow transplant recipients.

Authors:  G R De La Rosa; R E Champlin; D P Kontoyiannis
Journal:  Transpl Infect Dis       Date:  2002-03       Impact factor: 2.228

3.  Invasive aspergillosis in haematological malignancies: clinical findings and management for intensive chemotherapy completion.

Authors:  A Nosari; P Oreste; R Cairoli; M Montillo; G Carrafiello; A Astolfi; G Muti; L Marbello; A Tedeschi; E Magliano; E Morra
Journal:  Am J Hematol       Date:  2001-12       Impact factor: 10.047

4.  Prior invasive pulmonary and cerebellar mucormycosis is not a primary contraindication to perform an autologous stem cell transplatation in leukemia.

Authors:  A Tedeschi; M Montillo; R Cairoli; P Marenco; A Cafro; P Oreste; A Nosari; E Morra
Journal:  Leuk Lymphoma       Date:  2002-03

5.  Autologous peripheral blood stem cell transplant in patients previously diagnosed with invasive aspergillosis.

Authors:  J Sevilla; D Hernandez-Maraver; M J Aguado; E Ojeda; M Morado; F Hernandez-Navarro
Journal:  Ann Hematol       Date:  2001-08       Impact factor: 3.673

6.  Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients.

Authors:  J R Perfect; M E Klotman; C C Gilbert; D D Crawford; G L Rosner; K A Wright; W P Peters
Journal:  J Infect Dis       Date:  1992-05       Impact factor: 5.226

7.  Surgical resection of persistent pulmonary fungus nodules and secondary prophylaxis are effective in preventing fungal relapse in patients receiving chemotherapy or bone marrow transplantation for leukemia.

Authors:  A Nosari; M Ravini; R Cairoli; P Cozzi; L Marbello; P Marenco; G Grillo; E Morra
Journal:  Bone Marrow Transplant       Date:  2007-03-26       Impact factor: 5.483

8.  Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study.

Authors:  Catherine Cordonnier; Montserrat Rovira; Johan Maertens; Eduardo Olavarria; Catherine Faucher; Karin Bilger; Arnaud Pigneux; Oliver A Cornely; Andrew J Ullmann; Rodrigo Martino Bofarull; Rafael de la Cámara; Maja Weisser; Effie Liakopoulou; Manuel Abecasis; Claus Peter Heussel; Marc Pineau; Per Ljungman; Hermann Einsele
Journal:  Haematologica       Date:  2010-07-15       Impact factor: 9.941

9.  Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients.

Authors:  C Cordonnier; S Maury; C Pautas; J N Bastié; S Chehata; S Castaigne; M Kuentz; S Bretagne; P Ribaud
Journal:  Bone Marrow Transplant       Date:  2004-05       Impact factor: 5.483

Review 10.  Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group.

Authors:  Rinaldo Bellomo; Claudio Ronco; John A Kellum; Ravindra L Mehta; Paul Palevsky
Journal:  Crit Care       Date:  2004-05-24       Impact factor: 9.097
View more
  7 in total

1.  Cryptococcosis in pregnancy and the postpartum period: Case series and systematic review with recommendations for management.

Authors:  Katelyn A Pastick; Elizabeth Nalintya; Lillian Tugume; Kenneth Ssebambulidde; Nicole Stephens; Emily E Evans; Jane Frances Ndyetukira; Edwin Nuwagira; Caleb Skipper; Conrad Muzoora; David B Meya; Joshua Rhein; David R Boulware; Radha Rajasingham
Journal:  Med Mycol       Date:  2020-04-01       Impact factor: 4.076

2.  Tolerability and outcome of once weekly liposomal amphotericin B for the prevention of invasive fungal infections in hematopoietic stem cell transplant patients with graft-versus-host disease.

Authors:  Huong Luu Tran; Zahra Mahmoudjafari; Michelle Rockey; Dave Henry; Dennis Grauer; Omar Aljitawi; Sunil Abhyankar; Siddhartha Ganguly; Tara Lin; Joseph McGuirk
Journal:  J Oncol Pharm Pract       Date:  2014-12-03       Impact factor: 1.809

3.  Caspofungin as secondary antifungal prophylaxis and subsequent maintenance antifungal prophylaxis therapy in hematological malignancy patients.

Authors:  Mingjuan Liu; Yan Li; Xiaoli Zhao; Yongqing Zhang; Bing Zhai; Qingyi Zhang; Lijun Wang; Yu Zhao; Honghua Li; Quanshun Wang; Chunji Gao; Wenrong Huang; Li Yu
Journal:  Int J Clin Exp Med       Date:  2015-07-15

4.  Breakthrough Invasive Mold Infections in the Hematology Patient: Current Concepts and Future Directions.

Authors:  Michail S Lionakis; Russell E Lewis; Dimitrios P Kontoyiannis
Journal:  Clin Infect Dis       Date:  2018-10-30       Impact factor: 9.079

5.  High weekly doses of liposomal amphotericin B as secondary prophylaxis after cerebral aspergillosis in a paediatric patient.

Authors:  Pierluigi Brazzola; Mario R Rossi
Journal:  Med Mycol Case Rep       Date:  2013-11-06

6.  Secondary antifungal prophylaxis in hematological malignancy patients with previous invasive fungal disease: a retrospective analysis.

Authors:  Mingjuan Liu; Yan Li; Yongqing Zhang; Xiaoli Zhao; Bing Zhai; Qingyi Zhang; Lijun Wang; Yu Zhao; Honghua Li; Quanshun Wang; Chunji Gao; Wenrong Huang; Li Yu
Journal:  PLoS One       Date:  2014-12-22       Impact factor: 3.240

7.  Breakthrough Mucormycosis Developing on Mucorales-Active Antifungals Portrays a Poor Prognosis in Patients with Hematologic Cancer.

Authors:  Dierdre B Axell-House; Sebastian Wurster; Ying Jiang; Andreas Kyvernitakis; Russell E Lewis; Jeffrey J Tarrand; Issam I Raad; Dimitrios P Kontoyiannis
Journal:  J Fungi (Basel)       Date:  2021-03-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.